Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 144 entries
Sorted by: Best Match Show Resources per page
Acanthamoeba encephalitis: A Case Report and Review of Therapy.

Surgical neurology international

Zamora A, Henderson H, Swiatlo E.
PMID: 24991471
Surg Neurol Int. 2014 May 09;5:68. doi: 10.4103/2152-7806.132239. eCollection 2014.

BACKGROUND: Acanthamoeba is a rare cause of encephalitis yet is associated with high mortality. Treatment protocols vary greatly and generally include combination therapy across a wide spectrum of antiinfective classes.CASE DESCRIPTION: A 63-year-old male who underwent renal transplantation presented...

Cite
Zamora A, Henderson H, Swiatlo E. Acanthamoeba encephalitis: A Case Report and Review of Therapy. Surg Neurol Int. 2014;5:68doi: 10.4103/2152-7806.132239.
Zamora, A., Henderson, H., & Swiatlo, E. (2014). Acanthamoeba encephalitis: A Case Report and Review of Therapy. Surgical neurology international, 568. https://doi.org/10.4103/2152-7806.132239
Zamora, A, et al. "Acanthamoeba encephalitis: A Case Report and Review of Therapy." Surgical neurology international vol. 5 (2014): 68. doi: https://doi.org/10.4103/2152-7806.132239
Zamora A, Henderson H, Swiatlo E. Acanthamoeba encephalitis: A Case Report and Review of Therapy. Surg Neurol Int. 2014 May 09;5:68. doi: 10.4103/2152-7806.132239. eCollection 2014. PMID: 24991471; PMCID: PMC4078452.
Copy Download .nbib Format: NLM
Cryptococcal meningitis: epidemiology and therapeutic options.

Clinical epidemiology

Sloan DJ, Parris V.
PMID: 24872723
Clin Epidemiol. 2014 May 13;6:169-82. doi: 10.2147/CLEP.S38850. eCollection 2014.

Cryptococcal meningitis causes morbidity and mortality worldwide. The burden of disease is greatest in middle- and low-income countries with a high incidence of human immunodeficiency virus (HIV) infection. Patients taking immunosuppressive drugs and some immunocompetent hosts are also at...

Cite
Sloan DJ, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options. Clin Epidemiol. 2014;6:169-82doi: 10.2147/CLEP.S38850.
Sloan, D. J., & Parris, V. (2014). Cryptococcal meningitis: epidemiology and therapeutic options. Clinical epidemiology, 6169-82. https://doi.org/10.2147/CLEP.S38850
Sloan, Derek J, and Parris, Victoria. "Cryptococcal meningitis: epidemiology and therapeutic options." Clinical epidemiology vol. 6 (2014): 169-82. doi: https://doi.org/10.2147/CLEP.S38850
Sloan DJ, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options. Clin Epidemiol. 2014 May 13;6:169-82. doi: 10.2147/CLEP.S38850. eCollection 2014. PMID: 24872723; PMCID: PMC4026566.
Copy Download .nbib Format: NLM
Limitation of the Benefit of Amphotericin-Flucytosine Combination Therapy in Patients With Lower Conscious Level: An Ecological Fallacy?.

Open forum infectious diseases

Wolbers M, Day JN.
PMID: 26110168
Open Forum Infect Dis. 2015 May 14;2(2):ofv069. doi: 10.1093/ofid/ofv069. eCollection 2015 Apr.

No abstract available.

Cite
Wolbers M, Day JN. Limitation of the Benefit of Amphotericin-Flucytosine Combination Therapy in Patients With Lower Conscious Level: An Ecological Fallacy?. Open Forum Infect Dis. 2015;2(2):ofv069doi: 10.1093/ofid/ofv069.
Wolbers, M., & Day, J. N. (2015). Limitation of the Benefit of Amphotericin-Flucytosine Combination Therapy in Patients With Lower Conscious Level: An Ecological Fallacy?. Open forum infectious diseases, 2(2), ofv069. https://doi.org/10.1093/ofid/ofv069
Wolbers, Marcel, and Day, Jeremy N. "Limitation of the Benefit of Amphotericin-Flucytosine Combination Therapy in Patients With Lower Conscious Level: An Ecological Fallacy?." Open forum infectious diseases vol. 2,2 (2015): ofv069. doi: https://doi.org/10.1093/ofid/ofv069
Wolbers M, Day JN. Limitation of the Benefit of Amphotericin-Flucytosine Combination Therapy in Patients With Lower Conscious Level: An Ecological Fallacy?. Open Forum Infect Dis. 2015 May 14;2(2):ofv069. doi: 10.1093/ofid/ofv069. eCollection 2015 Apr. PMID: 26110168; PMCID: PMC4473111.
Copy Download .nbib Format: NLM
Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy.

Case reports in critical care

Kunka ME, Cady EA, Woo HC, Thompson Bastin ML.
PMID: 26246919
Case Rep Crit Care. 2015;2015:927496. doi: 10.1155/2015/927496. Epub 2015 Jul 12.

Purpose. A case report evaluating flucytosine dosing in a critically ill patient receiving continuous renal replacement therapy. Summary. This case report outlines an 81-year-old male who was receiving continuous venovenous hemofiltration (CVVH) for acute renal failure and was being...

Cite
Kunka ME, Cady EA, Woo HC, et al. Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy. Case Rep Crit Care. 2015;2015:927496doi: 10.1155/2015/927496.
Kunka, M. E., Cady, E. A., Woo, H. C., & Thompson Bastin, M. L. (2015). Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy. Case reports in critical care, 2015927496. https://doi.org/10.1155/2015/927496
Kunka, Megan E, et al. "Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy." Case reports in critical care vol. 2015 (2015): 927496. doi: https://doi.org/10.1155/2015/927496
Kunka ME, Cady EA, Woo HC, Thompson Bastin ML. Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy. Case Rep Crit Care. 2015;2015:927496. doi: 10.1155/2015/927496. Epub 2015 Jul 12. PMID: 26246919; PMCID: PMC4515255.
Copy Download .nbib Format: NLM
Persistent Cryptococcal Brain Infection despite Prolonged Immunorecovery in an HIV-Positive Patient.

Case reports in neurological medicine

Wingfield T, Baxter J, Herwadkar A, du Plessis D, Blanchard TJ, Javier Vilar F, Varma A.
PMID: 24716014
Case Rep Neurol Med. 2014;2014:164826. doi: 10.1155/2014/164826. Epub 2014 Mar 05.

Background. HIV-positive people starting combined antiretroviral therapy may develop immune reconstitution to latent or treated opportunistic infections. Immune reconstitution to cerebral Cryptococcus is poorly understood and can be fatal. Case Presentation. A 33-year-old Zimbabwean female presented with cryptococcal meningitis...

Cite
Wingfield T, Baxter J, Herwadkar A, et al. Persistent Cryptococcal Brain Infection despite Prolonged Immunorecovery in an HIV-Positive Patient. Case Rep Neurol Med. 2014;2014:164826doi: 10.1155/2014/164826.
Wingfield, T., Baxter, J., Herwadkar, A., du Plessis, D., Blanchard, T. J., Javier Vilar, F., & Varma, A. (2014). Persistent Cryptococcal Brain Infection despite Prolonged Immunorecovery in an HIV-Positive Patient. Case reports in neurological medicine, 2014164826. https://doi.org/10.1155/2014/164826
Wingfield, Tom, et al. "Persistent Cryptococcal Brain Infection despite Prolonged Immunorecovery in an HIV-Positive Patient." Case reports in neurological medicine vol. 2014 (2014): 164826. doi: https://doi.org/10.1155/2014/164826
Wingfield T, Baxter J, Herwadkar A, du Plessis D, Blanchard TJ, Javier Vilar F, Varma A. Persistent Cryptococcal Brain Infection despite Prolonged Immunorecovery in an HIV-Positive Patient. Case Rep Neurol Med. 2014;2014:164826. doi: 10.1155/2014/164826. Epub 2014 Mar 05. PMID: 24716014; PMCID: PMC3970336.
Copy Download .nbib Format: NLM
Candiduria: When and How to Treat It.

Current infectious disease reports

Fisher JF.
PMID: 11095903
Curr Infect Dis Rep. 2000 Dec;2(6):523-530. doi: 10.1007/s11908-000-0056-2.

The clinical finding of candiduria is often an enigmatic problem for the evaluating physician. The significance of yeast in the urine can range from procurement contamination to a sign of a life-threatening, opportunistic fungal infection. Proper evaluation requires validation...

Cite
Fisher JF. Candiduria: When and How to Treat It. Curr Infect Dis Rep. 2000;2(6):523-530doi: 10.1007/s11908-000-0056-2.
Fisher, J. F. (2000). Candiduria: When and How to Treat It. Current infectious disease reports, 2(6), 523-530. https://doi.org/10.1007/s11908-000-0056-2
Fisher. "Candiduria: When and How to Treat It." Current infectious disease reports vol. 2,6 (2000): 523-530. doi: https://doi.org/10.1007/s11908-000-0056-2
Fisher JF. Candiduria: When and How to Treat It. Curr Infect Dis Rep. 2000 Dec;2(6):523-530. doi: 10.1007/s11908-000-0056-2. PMID: 11095903.
Copy Download .nbib Format: NLM
Drug resistance in Cryptococcus neoformans.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Perfect JR, Cox GM.
PMID: 11504497
Drug Resist Updat. 1999 Aug;2(4):259-269. doi: 10.1054/drup.1999.0090.

Cryptococcus neoformans has become a major opportunistic fungal pathogen worldwide. Successful treatment of invasive disease with this fungus has used amphotericin B, flucytosine and various azoles. However, treatment failures continue to occur for a variety of reasons including direct...

Cite
Perfect JR, Cox GM. Drug resistance in Cryptococcus neoformans. Drug Resist Updat. 1999;2(4):259-269doi: 10.1054/drup.1999.0090.
Perfect, J. R., & Cox, G. M. (1999). Drug resistance in Cryptococcus neoformans. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2(4), 259-269. https://doi.org/10.1054/drup.1999.0090
Perfect, John R., and Cox, Gary M.. "Drug resistance in Cryptococcus neoformans." Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy vol. 2,4 (1999): 259-269. doi: https://doi.org/10.1054/drup.1999.0090
Perfect JR, Cox GM. Drug resistance in Cryptococcus neoformans. Drug Resist Updat. 1999 Aug;2(4):259-269. doi: 10.1054/drup.1999.0090. PMID: 11504497.
Copy Download .nbib Format: NLM
[Minimal inhibitory concentrations of Candida species to five antifungals by using the reference dilution micromethod and the E-test.].

Revista iberoamericana de micologia

Torres-Rodríguez JM, Madrenys N, Jiménez T, Saballs P.
PMID: 17655386
Rev Iberoam Micol. 1997 Sep;14(3):115-8.

It is accepted that the frequency of candidosis has increased during the last decade, specially in hospitalized patients. The more frequent use of azole antifungals and the recognition of isolates of Candida sp resistant to these and other drugs...

Cite
Torres-Rodríguez JM, Madrenys N, Jiménez T, et al. Concentraciones mínimas inhibitorias de levaduras a cinco antifúngicos utilizando un micrométodo de dilución estandarizado y el E-test. [Minimal inhibitory concentrations of Candida species to five antifungals by using the reference dilution micromethod and the E-test.]. Rev Iberoam Micol. 1997;14(3):115-8
Torres-Rodríguez, J. M., Madrenys, N., Jiménez, T., & Saballs, P. (1997). Concentraciones mínimas inhibitorias de levaduras a cinco antifúngicos utilizando un micrométodo de dilución estandarizado y el E-test. [Minimal inhibitory concentrations of Candida species to five antifungals by using the reference dilution micromethod and the E-test.]. Revista iberoamericana de micologia, 14(3), 115-8.
Torres-Rodríguez, J M, et al. "Concentraciones mínimas inhibitorias de levaduras a cinco antifúngicos utilizando un micrométodo de dilución estandarizado y el E-test." [Minimal inhibitory concentrations of Candida species to five antifungals by using the reference dilution micromethod and the E-test.]. Revista iberoamericana de micologia vol. 14,3 (1997): 115-8.
Torres-Rodríguez JM, Madrenys N, Jiménez T, Saballs P. Concentraciones mínimas inhibitorias de levaduras a cinco antifúngicos utilizando un micrométodo de dilución estandarizado y el E-test. [Minimal inhibitory concentrations of Candida species to five antifungals by using the reference dilution micromethod and the E-test.]. Rev Iberoam Micol. 1997 Sep;14(3):115-8. Spanish. PMID: 17655386.
Copy Download .nbib Format: NLM
[In vitro resistance to fluconazole and itraconazole in clinical isolates of Candida spp and Cryptococcus neoformans].

Revista iberoamericana de micologia

Carrillo Muñoz AJ, Tur C, Estivill D, Montsant L, Carceller A, Hernández-Molina JM, Torres Rodríguez JM.
PMID: 16854170
Rev Iberoam Micol. 1997 Jun;14(2):50-4.

An in vitro susceptibility testing of 181 strains of six species of Candida and 21 strains of Cryptococcus neoformans was carried out in order to investigate the resistance to new antifungal drugs. We have studied clinical isolates from 200...

Cite
Carrillo Muñoz AJ, Tur C, Estivill D, et al. Resistencia in vitro al fluconazol e itraconazol en aislamientos clínicos de Candida spp y Cryptococcus neoformans. [In vitro resistance to fluconazole and itraconazole in clinical isolates of Candida spp and Cryptococcus neoformans]. Rev Iberoam Micol. 1997;14(2):50-4
Carrillo Muñoz, A. J., Tur, C., Estivill, D., Montsant, L., Carceller, A., Hernández-Molina, J. M., & Torres Rodríguez, J. M. (1997). Resistencia in vitro al fluconazol e itraconazol en aislamientos clínicos de Candida spp y Cryptococcus neoformans. [In vitro resistance to fluconazole and itraconazole in clinical isolates of Candida spp and Cryptococcus neoformans]. Revista iberoamericana de micologia, 14(2), 50-4.
Carrillo Muñoz, A J, et al. "Resistencia in vitro al fluconazol e itraconazol en aislamientos clínicos de Candida spp y Cryptococcus neoformans." [In vitro resistance to fluconazole and itraconazole in clinical isolates of Candida spp and Cryptococcus neoformans]. Revista iberoamericana de micologia vol. 14,2 (1997): 50-4.
Carrillo Muñoz AJ, Tur C, Estivill D, Montsant L, Carceller A, Hernández-Molina JM, Torres Rodríguez JM. Resistencia in vitro al fluconazol e itraconazol en aislamientos clínicos de Candida spp y Cryptococcus neoformans. [In vitro resistance to fluconazole and itraconazole in clinical isolates of Candida spp and Cryptococcus neoformans]. Rev Iberoam Micol. 1997 Jun;14(2):50-4. Spanish. PMID: 16854170.
Copy Download .nbib Format: NLM
Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale

St-Germain G, Laverdière M, Pelletier R, René P, Bourgault AM, Lemieux C, Libman M.
PMID: 19145263
Can J Infect Dis Med Microbiol. 2008 Jan;19(1):55-62. doi: 10.1155/2008/634046.

BACKGROUND: Between May 2003 and April 2005, a population-based surveillance of Candida bloodstream infections was conducted in Quebec. A total of 453 episodes of candidemia (464 yeast isolates) from 54 participating hospitals were studied.RESULTS: The annual incidence rate was...

Cite
St-Germain G, Laverdière M, Pelletier R, et al. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol. 2008;19(1):55-62doi: 10.1155/2008/634046.
St-Germain, G., Laverdière, M., Pelletier, R., René, P., Bourgault, A. M., Lemieux, C., & Libman, M. (2008). Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 19(1), 55-62. https://doi.org/10.1155/2008/634046
St-Germain, Guy, et al. "Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005." The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale vol. 19,1 (2008): 55-62. doi: https://doi.org/10.1155/2008/634046
St-Germain G, Laverdière M, Pelletier R, René P, Bourgault AM, Lemieux C, Libman M. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol. 2008 Jan;19(1):55-62. doi: 10.1155/2008/634046. PMID: 19145263; PMCID: PMC2610277.
Copy Download .nbib Format: NLM
Recent advances in management of cryptococcal meningitis: commentary.

F1000 medicine reports

Sorrell TC, Chen SC.
PMID: 21170376
F1000 Med Rep. 2010 Nov 24;2:82. doi: 10.3410/M2-82.

Cryptococcal meningitis remains a substantial health burden with high morbidity, particularly in developing countries. Antifungal treatment regimens are guided by host factors, severity of illness (including presence of complications), and causative cryptococcal species. Recent clinical studies indicate the need...

Cite
Sorrell TC, Chen SC. Recent advances in management of cryptococcal meningitis: commentary. F1000 Med Rep. 2010;2:82doi: 10.3410/M2-82.
Sorrell, T. C., & Chen, S. C. (2010). Recent advances in management of cryptococcal meningitis: commentary. F1000 medicine reports, 282. https://doi.org/10.3410/M2-82
Sorrell, Tania C, and Chen, Sharon C-A. "Recent advances in management of cryptococcal meningitis: commentary." F1000 medicine reports vol. 2 (2010): 82. doi: https://doi.org/10.3410/M2-82
Sorrell TC, Chen SC. Recent advances in management of cryptococcal meningitis: commentary. F1000 Med Rep. 2010 Nov 24;2:82. doi: 10.3410/M2-82. PMID: 21170376; PMCID: PMC2998879.
Copy Download .nbib Format: NLM
Cryptococcal meningitis: current approaches to management in patients with and without AIDS.

Current infectious disease reports

Brizendine KD, Pappas PG.
PMID: 21308545
Curr Infect Dis Rep. 2010 Jul;12(4):299-305. doi: 10.1007/s11908-010-0113-4.

Cryptococcal meningitis is a life-threatening fungal infection of the central nervous system (CNS). Its management is characterized by the administration of initial combination antifungal therapy by following the principles of induction, consolidation, and maintenance therapy with aggressive management of...

Cite
Brizendine KD, Pappas PG. Cryptococcal meningitis: current approaches to management in patients with and without AIDS. Curr Infect Dis Rep. 2010;12(4):299-305doi: 10.1007/s11908-010-0113-4.
Brizendine, K. D., & Pappas, P. G. (2010). Cryptococcal meningitis: current approaches to management in patients with and without AIDS. Current infectious disease reports, 12(4), 299-305. https://doi.org/10.1007/s11908-010-0113-4
Brizendine, Kyle D, and Pappas, Peter G. "Cryptococcal meningitis: current approaches to management in patients with and without AIDS." Current infectious disease reports vol. 12,4 (2010): 299-305. doi: https://doi.org/10.1007/s11908-010-0113-4
Brizendine KD, Pappas PG. Cryptococcal meningitis: current approaches to management in patients with and without AIDS. Curr Infect Dis Rep. 2010 Jul;12(4):299-305. doi: 10.1007/s11908-010-0113-4. PMID: 21308545.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 144 entries